Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiogenesis
Research from Beth Israel Deaconess Medical Center, Division of Hematology-Oncology has provided new data on angiogenesis
March 2nd, 2007
Research findings, "Biomarkers for monitoring antiangiogenic therapy," are discussed in a new report. According to a study from the United States, "A variety of antiangiogenic agents are currently available for the treatment of renal cell carcinoma. With these exciting new therapeutic agents comes the challenge of elucidating useful biomarkers to monitor patients receiving these therapies." "Although many patients benefit from antiangiogenic therapies, it is often by achieving stability of their disease. Thus, development of noninvasive biomarkers of disease response and relapse is a crucial objective to aid in the management of patients. The current technologies being...
Source: Drug Week (2007-03-02)
|
